Logo

Zyomyx Signs on GlaxoSmithKline for Protein Biochips

Aug 16, 2002

NEW YORK, Aug. 16-GlaxoSmithKline has agreed to be an early access customer of Zyomyx's line of protein biochips, Zyomyx said today.

 

Zyomyx has developed biochips and a profiling system that permits researchers to track expression of 30 human cytokines in serum samples. According to the company, the system can be used in drug discovery, target validation, biomarker studies and drug candidate evaluation.

 

The companies did not reveal financial details of the agreement.

 

The clinical testing company Specialty Laboratories also has an early access agreement with Zyomyx.

 

Breaking News
The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.